Kisho

Medimmune Oncology, Inc. — Rare Disease Pipeline | Kisho | Kisho

Medimmune Oncology, Inc.

Other

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
Adams-Oliver syndrome 1	Ethyol	Orphan Designation	-
Bicervical bicornuate uterus with patent cervix and vagina	Trimetrexate glucuronate	Orphan Designation	-
Gorham-Stout disease	Ethyol	Orphan Designation	-
Luscan-Lumish syndrome	Ethyol	Orphan Designation	-
Pneumocystis infectious disease	Neutrexin	Orphan Designation	-
advanced heart failure	EthyolHexalen	Orphan Designation	-
advanced sleep phase syndrome	EthyolHexalen	Orphan Designation	-
advanced sleep phase syndrome 1	Hexalen	Orphan Designation	-
advanced sleep phase syndrome 2	Hexalen	Orphan Designation	-
advanced sleep phase syndrome 3	EthyolHexalen	Orphan Designation	-
autosomal semi-dominant severe lipodystrophic laminopathy	Ethyol	Orphan Designation	-
bladder neck cancer	Ethyol	Orphan Designation	-
carbon monoxide-induced delayed encephalopathy	Trimetrexate glucuronate	Orphan Designation	-
fibrous dysplasia	Ethyol	Orphan Designation	-
head and neck cancer	Ethyol	Orphan Designation	-
head and neck carcinoma	Ethyol	Orphan Designation	-
malignant tumor of neck	Ethyol	Orphan Designation	-
medial condensing osteitis of the clavicle	Ethyol	Orphan Designation	-
metastatic malignant neoplasm in the colon	Trimetrexate	Orphan Designation	-
metastatic melanoma	Trimetrexate	Orphan Designation	-
metastatic neoplasm	Trimetrexate	Orphan Designation	-
mitochondrial DNA depletion syndrome 9	Hexalen	Orphan Designation	-
pancreatic adenocarcinoma	Trimetrexate glucuronate	Orphan Designation	-
pneumocystosis	Neutrexin	Orphan Designation	-
severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome	Neutrexin	Orphan Designation	-
skeletal dysplasia, mild, with joint laxity and advanced bone age	Trimetrexate glucuronate	Orphan Designation	-
thyroid gland carcinoma	Ethyol	Orphan Designation	-

← Back to Companies